Condition 1: Multiple myeloma. Condition 2: Non-Hodgkin lymphoma. Condition 3: Hodgkin lymphoma. Condition 4: Myelodysplastic syndrome. Multiple myeloma and malignant plasma cell neoplasms Hodgkin lymphoma Hodgkin lymphoma Myelodysplastic syndromes
Conditions
Interventions
Intervention 1: Intervention group 1: injection of one homologous booster dose of Pastocovac 4 weeks (±7 days) after receiving two doses of primary Pastocovac vaccine, that is injected intramuscularly
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients who have undergone autologous hematopoietic stem cell transplantation Between 6 months and 12 months after transplantation They have received two initial doses of Pastocovac vaccine At least one month after receiving the second dose
Exclusion criteria
Exclusion criteria: Treatment with rituximab during last 6 months Relapse of underlying disease Positive rapid COVID-19 test before booster dose vaccination Patients who do not consent to vaccination
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 antibody titers. Timepoint: before the start of the intervention and 4 weeks (±7 days) after the injection of the booster dose vaccine. Method of measurement: ChemoBind SARS-CoV-? IgG Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Probable Side effect: local pain, fever, fatigue, headache and sore throat. Timepoint: One week after vaccination. Method of measurement: Vaccine side effects checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeyla Sharifi Aliabadi
Tehran University of Medical Sciences
Outcome results
None listed